HPS Pharmacies wish to advise that Boehringer Ingelheim is experiencing a supply interruption for Actilyse® as follows:
Alteplase (rch) 10mg
Alteplase (rch) 50mg
This supply interruption is expected to resolve by the end of December 2023.
During this period, Boehringer Ingelheim will be closely controlling supplies of both alteplase and tenecteplase. The product information for Metalyse® and Actilyse® are available from the Therapeutic Goods Administration (TGA).
Internationally registered alternative brands have been approved for supply under Section 19A of the Therapeutic Goods Act 1989. However, supplies of these alternatives may not be stable.
Further information, including clinical recommendations, is available on the TGA website.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Boehringer Ingelheim on 1800 226 315 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates